Sharma Sonam, Bekelman Justin, Lin Alexander, Lukens J Nicholas, Roman Benjamin R, Mitra Nandita, Swisher-McClure Samuel
Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, United States.
Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, United States.
Oral Oncol. 2016 May;56:17-24. doi: 10.1016/j.oraloncology.2016.02.010. Epub 2016 Mar 16.
PURPOSE/OBJECTIVE(S): We examined practice patterns using the National Cancer Data Base (NCDB) to determine risk factors for prolonged diagnosis to treatment interval (DTI) and survival outcomes in patients receiving chemoradiation for oropharyngeal squamous cell carcinoma (OPSCC).
We identified 6606 NCDB patients with Stage III-IV OPSCC receiving chemoradiation from 2003 to 2006. We determined risk factors for prolonged DTI (>30days) using univariate and multivariable logistic regression models. We examined overall survival (OS) using Kaplan Meier and multivariable Cox proportional hazards models.
3586 (54.3%) patients had prolonged DTI. Race, IMRT, insurance status, and high volume facilities were significant risk factors for prolonged DTI. Patients with prolonged DTI had inferior OS compared to DTI⩽30days (Hazard Ratio (HR)=1.12, 95% CI 1.04-1.20, p=0.005). For every week increase in DTI there was a 2.2% (95% CI 1.1-3.3%, p<0.001) increase in risk of death. Patients receiving IMRT, treatment at academic, or high-volume facilities were more likely to experience prolonged DTI (High vs. Low volume: 61.5% vs. 51.8%, adjusted OR 1.38, 95% CI 1.21-1.58; Academic vs. Community: 59.5% vs. 50.6%, adjusted OR 1.26, 95% CI 1.13-1.42; non-IMRT vs. IMRT: 53.4% vs. 56.5%; adjusted OR 1.17, 95% CI 1.04-1.31).
Our results suggest that prolonged DTI has a significant impact on survival outcomes. We observed disparities in DTI by socioeconomic factors. However, facility level factors such as academic affiliation, high volume, and IMRT also increased risk of DTI. These findings should be considered in developing efficient pathways to mitigate adverse effects of prolonged DTI.
我们利用国家癌症数据库(NCDB)研究了治疗模式,以确定口咽鳞状细胞癌(OPSCC)接受放化疗患者诊断至治疗间隔时间(DTI)延长的风险因素及生存结果。
我们在NCDB中识别出2003年至2006年间接受放化疗的6606例III-IV期OPSCC患者。我们使用单变量和多变量逻辑回归模型确定DTI延长(>30天)的风险因素。我们使用Kaplan-Meier法和多变量Cox比例风险模型研究总生存期(OS)。
3586例(54.3%)患者的DTI延长。种族、调强放射治疗(IMRT)、保险状况和大型医疗机构是DTI延长的显著风险因素。与DTI≤30天的患者相比,DTI延长的患者总生存期较差(风险比(HR)=1.12,95%置信区间1.04-1.20,p=0.005)。DTI每增加一周,死亡风险增加2.2%(95%置信区间1.1-3.3%,p<0.001)。接受IMRT治疗、在学术或大型医疗机构治疗的患者更有可能出现DTI延长(大型机构与小型机构:61.5%对51.8%,校正后比值比1.38,95%置信区间1.21-1.58;学术机构与社区机构:59.5%对50.6%,校正后比值比1.26;95%置信区间1.13-1.42;非IMRT与IMRT:53.4%对56.5%,校正后比值比1.17,95%置信区间1.04-1.31)。
我们的结果表明,DTI延长对生存结果有显著影响。我们观察到社会经济因素导致的DTI差异。然而,机构层面的因素,如学术隶属关系、大型机构和IMRT,也增加了DTI延长的风险。在制定有效途径以减轻DTI延长的不利影响时应考虑这些发现。